FDA approves expansion of Lipitor label
The U.S. Food and Drug Administration has approved expanded use of Pfizer Inc's blockbuster cholesterol-lowering medicine Lipitor by five new categories, including one to reduce the risk of non-fatal heart attacks and strokes, the company said on Wednesday.
Pfizer wins U.S. approval for new HIV drug
Pfizer Inc said on Monday that U.S. regulators approved its AIDS drug, Selzentry, the first in a new class of oral HIV medicines.
J&J to cut jobs in restructuring
Johnson & Johnson said on Tuesday it planned to eliminate 3 percent to 4 percent of its global work force of about 120,500 people as part of a plan to improve its cost structure. The cost-cutting plan is expected to generate pretax cost savings of $1.3 billion to $1.6 billion in 2008, the diversified health care company said.
Pfizer profit falls short, Lipitor disappoints
Pfizer Inc. on Wednesday reported lower-than-expected quarterly earnings on competition with generics, and said global sales of cholesterol fighter Lipitor fell 13 percent amid slipping demand for the company's flagship product.
Weak J&J forecast sours strong quarterly results
Johnson & Johnson on Tuesday stuck with its 2007 earnings forecast despite surprisingly strong second-quarter results, sending shares down more than 1.7 percent.
Merck, Nycomed stoke European drugs merger
Consolidation in Europe's drugs sector gathered steam on Thursday as Germany's Merck unveiled a $13.3-billion deal to buy Europe's top biotech firm Serono, and Denmark's Nycomed won the drugs unit of Altana.
Wall St Set for Lackluster Start; Lehman in Focus
Wall Street stocks are set for a muted start to Wednesday trade as investors consolidate positions after the push to four-month highs, with crude oil trading at $64 a barrel helping ease inflation concerns.
Pfizer Posts 30 Pct. Profit Decrease in 2Q
Pfizer, the world's largest drug maker, posted a 30 percent decrease in net income for the second quarter on Thursday as it faces strong challenges from generic competitors in the market after losing its patent rights over two of the most profitable drug for the firm.
Bayer Not Seeking Pfizer Consumer Health Unit
German drugs and chemicals group Bayer is not currently considering a bid for Pfizer's consumer healthcare business, an industry source familiar with the matter told Reuters on Saturday.
FTSE ends higher, bid talk boosts BAA, Corus
Leading UK shares closed higher on Friday but finished the week with a moderate loss as the market's recent choppy trading pattern, sparked by inflation and interest rate jitters, persisted.